Skip to content
logo MSD Oncology Clinical Trials
  • Início
  • Estudos
    • Menu principal
    • Visão geral do teste
    • Bexiga
    • Cabeça e Pescoço
    • Colorretal
    • Esofágico
    • Fígado e via Biliar
    • Gástrico
    • Ginecológico
    • Hematológico
    • Mama
    • Melanoma
    • Pediátrico
    • Próstata
    • Pulmão
    • Rim
    • Tumores Sólidos
  • Sobre
  • Perguntas frequentes
  • Para Profissionais Da Saúde
  • Português (BR)
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Trial Status: Ativo, não recrutando

O principal objetivo deste estudo é avaliar a atividade antitumoral e a segurança de lenvatinibe (MK-7902/E7080) em crianças, adolescentes e jovens adultos com malignidades sólidas recidivadas ou refratárias após a administração. Os participantes serão incluídos em coortes iniciais específicas do tumor, que serão expandidas com base na resposta observada.

Trial Status: Ativo, não recrutando

Estudo de lenvatinibe em participantes pediátricos com malignidades sólidas recidivantes ou refratárias

March 10, 2022

By Support_Clique

The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration.

Eficácia, segurança e tolerabilidade de V937 administrado por via intravenosa ou intratumoral com pembrolizumabe versus pembrolizumabe isoladamente em participantes com melanoma avançado/metastático

March 10, 2022

By Support_Clique

This is a Phase 2 study to assess the efficacy, safety, and tolerability of V937 administered both intratumorally (ITu) and intravenously (IV) as combination therapy with pembrolizumab (MK-3475) versus pembrolizumab alone

Segurança e eficácia de pembrolizumabe versus placebo como terapia adjuvante em participantes com carcinoma hepatocelular e resposta radiológica completa após ressecção cirúrgica ou ablação local

March 10, 2022

By clique_admin

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local

Pembrolizumab as First-line Therapy for Advanced Merkel Cell Carcinoma

March 10, 2022

By clique_admin

This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial

Estudo de pembrolizumabe mais quimioterapia em participantes com adenocarcinoma gástrico ou da junção gastroesofágica (JGE)

March 10, 2022

By Support_Clique

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen]) versus

Segurança e eficácia de lenvatinibe em combinação com pembrolizumabe versus lenvatinibe como terapia de primeira linha em participantes com carcinoma hepatocelular avançado

March 10, 2022

By Tyler Kalist

The purpose of this study is to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3745) versus lenvatinib in combination with placebo as first-line therapy for the

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC.

March 10, 2022

By clique_admin

This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy

Pembrolizumabe/placebo mais trastuzumabe mais quimioterapia em adenocarcinoma gástrico ou de junção gastroesofágica avançado positivo para receptor do fator de crescimento epidérmico humano 2

March 10, 2022

By Support_Clique

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive

Estudo de pembrolizumabe mais quimioterapia versus placebo mais quimioterapia em participantes com adenocarcinoma gástrico ou da junção gastroesofágica

March 10, 2022

By Support_Clique

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and

Estudo de segurança e eficácia de pembrolizumabe como monoterapia no tratamento adjuvante de carcinoma de células renais pós-nefrectomia

March 10, 2022

By Tyler Kalist

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have undergone nephrectomy and have intermediate-high risk, high

Posts navigation

Older posts
logo-white MSD Oncology Clinical Trials
  • Política de privacidade MSD
  • Termos de uso
  • Preferências de cookies
  • Acessibilidade

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

Acessibilidade

Acessibilidade